Abstract
Intravenous immunoglobulin (IVIg) has been used as an immunomodulatory therapy for the treatment of multiple sclerosis (MS). In the current review, we summarize the up-to-date data related to IVIg clinical trials in MS, and the suggested mechanisms of action by which IVIg modulates the relevant immunological pathways impaired in MS.
| Original language | English |
|---|---|
| Pages (from-to) | 247-254 |
| Number of pages | 8 |
| Journal | Clinical Reviews in Allergy and Immunology |
| Volume | 29 |
| Issue number | 3 |
| DOIs | |
| State | Published - Dec 2005 |
Keywords
- Autoimmunity
- Immune system diseases
- Intravenous immunoglobulins
- Mechanisms
- Multiple sclerosis